S
19.86
-0.55 (-2.69%)
| Previous Close | 20.41 |
| Open | 20.06 |
| Volume | 532,055 |
| Avg. Volume (3M) | 757,066 |
| Market Cap | 842,085,888 |
| Price / Book | 3.08 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -1.50 |
| Total Debt/Equity (MRQ) | 2.70% |
| Current Ratio (MRQ) | 28.73 |
| Operating Cash Flow (TTM) | -55.90 M |
| Levered Free Cash Flow (TTM) | -40.48 M |
| Return on Assets (TTM) | -37.10% |
| Return on Equity (TTM) | -61.44% |
AIStockmoo Score
0.5
| Analyst Consensus | 5.0 |
| Insider Activity | -3.5 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 0.5 |
| Average | 0.50 |
| % Held by Insiders | 7.20% |
| % Held by Institutions | 93.91% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 46.00 (Jones Trading, 131.62%) | Buy |
| Median | 45.00 (126.59%) | |
| Low | 22.00 (RBC Capital, 10.78%) | Hold |
| Average | 37.67 (89.68%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 23.57 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jones Trading | 08 Sep 2025 | 46.00 (131.62%) | Buy | 21.62 |
| RBC Capital | 03 Sep 2025 | 22.00 (10.78%) | Hold | 24.55 |
| Raymond James | 03 Sep 2025 | 45.00 (126.59%) | Buy | 24.55 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FITZPATRICK JENNIFER | - | 23.06 | -10,250 | -236,365 |
| RIDLOFF ELENA | - | 25.01 | -9,584 | -242,762 |
| Aggregate Net Quantity | -19,834 | |||
| Aggregate Net Value ($) | -479,127 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 24.36 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FITZPATRICK JENNIFER | Officer | 04 Sep 2025 | Automatic sell (-) | 10,250 | 23.06 | 236,365 |
| FITZPATRICK JENNIFER | Officer | 04 Sep 2025 | Option execute | 10,250 | - | - |
| RIDLOFF ELENA | Officer | 02 Sep 2025 | Automatic sell (-) | 8,836 | 25.39 | 224,346 |
| RIDLOFF ELENA | Officer | 29 Aug 2025 | Automatic sell (-) | 748 | 24.62 | 18,416 |
| Date | Type | Details |
|---|---|---|
| 08 Sep 2025 | Announcement | Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer |
| 27 Aug 2025 | Announcement | Sionna Therapeutics to Participate in Upcoming September Investor Conferences |
| 25 Aug 2025 | Announcement | Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis |
| 11 Aug 2025 | Announcement | Sionna Therapeutics Reports Second Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |